Clinical significance of human papilloma virus infection in the cervical lesions

doi:10.1007/s11684-010-0094-6

Front Med Chin

2010, Vol. 4

Issue (3) : 264-270 https://doi.org/10.1007/s11684-010-0094-6

REVIEW

Clinical significance of human papilloma virus infection in the cervical lesions

Shuang LI¹, Yu-Han MENG¹, Hu TING¹, Jian SHEN², Ding MA¹(

)

1. Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 2. Wuhan Central Hospital, Wuhan 430014, China

Download: PDF(118 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Cervical lesions have been regarded as the common and frequently occurring diseases in China. Recently, the morbidity and youth tendency of cervical cancer have gradually increased. Cervical cancer, related with human papilloma virus (HPV) infection, has been one of the severest diseases threatening health and life of women, and is an infectious disease. The universality of HPV infection in the reproductive tract should not be ignored. The well-known risk factors of HPV infection in cervical lesions consist of high-risk sexual behaviors, immunosuppression, age, contraceptive methods, the concurrent infection of other sexually transmitted diseases, etc. The variation of cervical lesions induced by HPV infection is involved in the continuous pathological process, including the subclinical, latent, and persistent infection of high risk (HR)-HPV, chronic cervicitis with abnormal results of cytological examination, cervical intraepithelial neoplasia (CIN), and cervical cancer. The outcome of patients with HPV infection is influenced by many factors, such as HPV subtype dominance, persistent HPV infection, HPV loading dose, and multiple HPV infection. Controlling HR-HPV persistent infection should be an important strategy for reducing cervical lesions.

Keywords cervical lesion high risk-human papilloma virus persistent infection loading dose cervical intraepithelial neoplasia cervical cancer

Corresponding Author(s): MA Ding,Email:dma@tjh.tjmu.edu.cn

Issue Date: 05 September 2010

Cite this article:

Shuang LI,Yu-Han MENG,Hu TING, et al. Clinical significance of human papilloma virus infection in the cervical lesions[J]. Front Med Chin, 2010, 4(3): 264-270.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0094-6
https://academic.hep.com.cn/fmd/EN/Y2010/V4/I3/264

1	Bekkers R L, Massuger L F, Bulten J, Melchers W J. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol , 2004, 14(2): 95–105 doi: 10.1002/rmv.416
2	Herrero R, Hildesheim A, Bratti C, Sherman M E, Hutchinson M, Morales J, Balmaceda I, Greenberg M D, Alfaro M, Burk R D, Wacholder S, Plummer M, Schiffman M. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst , 2000, 92(6): 464–474 doi: 10.1093/jnci/92.6.464
3	Infantolino C, Fabris P, Infantolino D, Biasin M R, Venza E, Tositti G, Minucci D. Usefulness of human papilloma virus testing in the screening of cervical cancer precursor lesions: a retrospective study in 314 cases. Eur J Obstet Gynecol Reprod Biol , 2000, 93(1): 71–75 doi: 10.1016/S0301-2115(99)00299-7
4	Sellors J W, Mahony J B, Kaczorowski J, Lytwyn A, Bangura H, Chong S, Lorincz A, Dalby D M, Janjusevic V, Keller J L. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ , 2000, 163(5): 503–508
5	Duttagupta C, Sengupta S, Roy M, Sengupta D, Chakraborty S, Bhattacharya P, Roy S, Ghosh S. Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer: a screening strategy in the perspective of rural India. Eur J Cancer Prev , 2002, 11(5): 447–456 doi: 10.1097/00008469-200210000-00007
6	Bosch F X, Lorincz A, Munoz N, Meijer C J, Shah K V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol , 2002, 55(4): 244–265
7	Deacon J M, Evans C D, Yule R, Desai M, Binns W, Taylor C, Peto J. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer , 2000, 83(11): 1565–1572 doi: 10.1054/bjoc.2000.1523
8	de Lima Soares V, de Mesquita A M, Cavalcante F G, Silva Z P, Hora V, Diedrich T, de Carvalho Silva P, de Melo P G, Dacal A R, de Carvalho E M, Feldmeier H. Sexually transmitted infections in a female population in rural north-east Brazil: prevalence, morbidity and risk factors. Trop Med Int Health , 2003, 8(7): 595–603 doi: 10.1046/j.1365-3156.2003.01078.x
9	Heard I P, Tassie J M P, Schmitz V P, Mandelbrot L, Kazatchkine M D, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol , 2000, 96(3): 403–409 doi: 10.1016/S0029-7844(00)00948-0
11	Stoler M H. Advances in cervical screening technology. Mod Pathol , 2000, 13(3): 275–284 doi: 10.1038/modpathol.3880048
12	Li L K, Dai M, Clifford G M, Yao W Q, Arslan A, Li N, Shi J F, Snijders P J, Meijer C J, Qiao Y L, Franceschi S. Human papillomavirus infection in Shenyang City, People’s Republic of China: A population-based study. Br J Cancer , 2006, 95(11): 1593–1597 doi: 10.1038/sj.bjc.6603450
13	Sellors J W, Karwalajtys T L, Kaczorowski J A, Mahony J B, Lytwyn A, Chong S, Sparrow J, Lorincz A; Survey of HPV in Older Ontario Women (SHOOW) Group. Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ , 2002, 167(8): 871–873
14	Ferrera A, Velema J P, Figueroa M, Bulnes R, Toro L A, Claros J M, de Barahona O, Melchers W J. Co-factors related to the causal relationship between human papillomavirus and invasive cervical cancer in Honduras. Int J Epidemiol , 2000, 29(5): 817–825 doi: 10.1093/ije/29.5.817
15	Walboomers J M, Jacobs M V, Manos M M, Bosch F X, Kummer J A, Shah K V, Snijders P J, Peto J, Meijer C J, Mu?oz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol , 1999, 189(1): 12–19 doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
16	Franceschi S, Herrero R, La Vecchia C. Cervical cancer screening in Europe. What next? Eur J Cancer , 2000, 36(17): 2272–2275 doi: 10.1016/S0959-8049(00)00340-3
17	Mu?oz N, Bosch F X, de Sanjosé S, Herrero R, Castellsagué X, Shah K V, Snijders P J, Meijer C J; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med , 2003, 348(6): 518–527 doi: 10.1056/NEJMoa021641
18	zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst , 2000, 92(9): 690–698 doi: 10.1093/jnci/92.9.690
19	Kulasingam S L, Hughes J P, Kiviat N B, Mao C, Weiss N S, Kuypers J M, Koutsky L A. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA , 2002, 288(14): 1749–1757
20	Liaw K L, Glass A G, Manos M M, Greer C E, Scott D R, Sherman M, Burk R D, Kurman R J, Wacholder S, Rush B B, Cadell D M, Lawler P, Tabor D, Schiffman M. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst , 1999, 91(11): 954–960 doi: 10.1093/jnci/91.11.954
21	Sherman M E, Lorincz A T, Scott D R, Wacholder S, Castle P E, Glass A G, Mielzynska-Lohnas I, Rush B B, Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst , 2003, 95(1): 46–52 doi: 10.1093/jnci/95.1.46
22	Kuhn L, Denny L, Pollack A, Lorincz A, Richart R M, Wright T C. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst , 2000, 92(10): 818–825 doi: 10.1093/jnci/92.10.818
23	Peh W L, Middleton K, Christensen N, Nicholls P, Egawa K, Sotlar K, Brandsma J, Percival A, Lewis J, Liu W J, Doorbar J. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol , 2002, 76(20): 10401–10416 doi: 10.1128/JVI.76.20.10401-10416.2002
24	Woodman C B, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason T P, Young L S. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet , 2001, 357(9271): 1831–1836
25	Yang Y J, Zhao J, Xue Q L. The associativity of the different subtypes of human papilloma virus infection and cervical lesions. Zhongguo Fu Chan Ke Li Chuang Za Zhi , 2006, 7(4): 253–256 (in Chinese)
26	Ru T H, Wei L H, Wu R F, Zhou Y Q. The subtype dominance of human papillomavirus infection in the different degrees of cervical lesions. Huazhong Keji Daxue Xebao (Yixueban) , 2006, 35(6): 771–773 (in Chinese)
27	Tsai H T, Wu C H, Lai H L, Li R N, Tung Y C, Chuang H Y, Wu T N, Lin L J, Ho C K, Liu H W, Wu M T. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prev , 2005, 14(11 Pt 1): 2544–2549 doi: 10.1158/1055-9965.EPI-05-0240
28	Schellekens M C, Dijkman A, Aziz M F, Siregar B, Cornain S, Kolkman-Uljee S, Peters L A, Fleuren G J. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol , 2004, 93(1): 49–53 doi: 10.1016/j.ygyno.2003.12.015
29	Deluca G D, Lucero R H, Martin de Civetta M T, Vicente L, de Gorodner O L, Schelover E, Alonso J M. Human papillomavirus genotypes in women with cervical cytological abnormalities from an area with high incidence of cervical cancer. Rev Inst Med Trop Sao Paulo , 2004, 46(1): 9–12 doi: 10.1590/S0036-46652004000100002
30	Bulk S, Berkhof J, Bulkmans N W, Zielinski G D, Rozendaal L, van Kemenade F J, Snijders P J, Meijer C J. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer , 2006, 94(1): 171–175 doi: 10.1038/sj.bjc.6602915
31	Altekruse S F, Lacey J V Jr, Brinton L A, Gravitt P E, Silverberg S G, Barnes W A Jr, Greenberg M D, Hadjimichael O C, McGowan L, Mortel R, Schwartz P E, Hildesheim A. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol , 2003, 188(3): 657–663 doi: 10.1067/mob.2003.132
32	Lombard I, Vincent-Salomon A, Validire P, Zafrani B, de la Rochefordiére A, Clough K, Favre M, Pouillart P, Sastre-Garau X. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol , 1998, 16(8): 2613–2619
33	Clifford G M, Smith J S, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer , 2003, 89(1): 101–105 doi: 10.1038/sj.bjc.6601024
34	Womack S D, Chirenje Z M, Gaffikin L, Blumenthal P D, McGrath J A, Chipato T, Ngwalle S, Munjoma M, Shah K V. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer , 2000, 85(2): 206–210
35	Damasus-Awatai G, Freeman-Wang T. Human papilloma virus and cervical screening. Curr Opin Obstet Gynecol , 2003, 15(6): 473–477 doi: 10.1097/00001703-200312000-00003
36	Schlecht N F, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura R A, Duarte-Franco E, Rohan T E, Ferenczy A, Villa L L, Franco E L. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA , 2001, 286(24): 3106–3114
37	Josefsson A M, Magnusson P K, Ylitalo N, S?rensen P, Qwarforth-Tubbin P, Andersen P K, Melbye M, Adami H O, Gyllensten U B. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet , 2000, 355(9222): 2189–2193 doi: 10.1016/S0140-6736(00)02401-6
38	Huang Z H, Qian D Y, Wang D, Cen J M, Shu Y H. The related research about Human papilloma viral loading dose and cervical precancerosis lesions and cervical cancer. Zhongguo Fuyou Baojian , 2006, 21(11): 1557–1559 (in Chinese)
39	Sun C A, Liu J F, Wu D M, Nieh S, Yu C P, Chu T Y. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gyne Obstet , 2002, 76(1): 41–47 doi: 10.1016/S0020-7292(01)00529-X
40	Sun C A, Lai H C, Chang C C, Neih S, Yu C P, Chu T Y. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol , 2001, 83(1): 95–99 doi: 10.1006/gyno.2001.6336
41	Schlecht N F, Trevisan A, Duarte-Franco E, Rohan T E, Ferenczy A, Villa L L, Franco E L. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer , 2003, 103(4): 519–524 doi: 10.1002/ijc.10846
42	Dalstein V, Riethmuller D, Prétet J L, Le Bail Carval K, Sautière J L, Carbillet J P, Kantelip B, Schaal J P, Mougin C. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer , 2003, 106(3): 396–403 doi: 10.1002/ijc.11222
44	Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer , 2005, 92(5): 891–894 doi: 10.1038/sj.bjc.6602436
45	Lorincz A T, Castle P E, Sherman M E, Scott D R, Glass A G, Wacholder S, Rush B B, Gravitt P E, Schussler J E, Schiffman M. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet , 2002, 360(9328): 228–229 doi: 10.1016/S0140-6736(02)09463-1
46	Ho G Y, Burk R D, Klein S, Kadish A S, Chang C J, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst , 1995, 87(18): 1365–1371 doi: 10.1093/jnci/87.18.1365
47	Burd E M. Human papillomavirus and cervical cancer. Clin Microbiol Rev , 2003, 16(1): 1–17 doi: 10.1128/CMR.16.1.1-17.2003
48	Lee S A, Kang D, Seo S S, Jeong J K, Yoo K Y, Jeon Y T, Kim J W, Park N H, Kang S B, Lee H P, Song Y S. Multiple HPV infection in cervical cancer screened by HPVDNAChip. Cancer Lett , 2003, 198(2): 187–192 doi: 10.1016/S0304-3835(03)00312-4

[1]	Yumeng Wang, Guiling Li. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives[J]. Front. Med., 2019, 13(4): 438-450.
[2]	Tian Wang, Yan Li, Abidan Tuerhanjiang, Wenwen Wang, Zhangying Wu, Ming Yuan, Shixuan Wang. Correlation of Twist upregulation and senescence bypass during the progression and metastasis of cervical cancer[J]. Front Med, 2014, 8(1): 106-112.
[3]	Shao-Ming WANG, Jing LI, You-Lin QIAO. HPV prevalence and genotyping in the cervix of Chinese women[J]. Front Med Chin, 2010, 4(3): 259-263.
[4]	Zhou-Fang XIONG MD, Wei-Hong DONG MD, Ze-Hua WANG MD, . Non-closure of the peritoneum and subcutaneous tissue at radical hysterectomy: A randomized controlled trial[J]. Front. Med., 2010, 4(1): 112-116.
[5]	Zhihua LIU MD, Qing LI BM, Weihong LI BM, . Epidemiological studies of women under age 30 infected with human papillomavirus[J]. Front. Med., 2009, 3(4): 459-462.
[6]	Guocheng LIU MD, Shouhua YANG MD, Zehua WANG MD, . The relationship between platelet-derived growth factor expression and angiogenesis/lymphangiogenesis in cervical cancer[J]. Front. Med., 2009, 3(4): 447-451.
[7]	Yuan ZHANG MD , Xiaoyan ZHANG MM , Yanhui LI MM , Xuan DU MM , Zehua WANG MD, PhD , Hongbo WANG MD , . Effects of phosphatidylinositol 3-kinase inhibitor on human cervical carcinoma cells [J]. Front. Med., 2009, 3(3): 341-346.

Viewed

Full text

Abstract

Cited

Shared

Discussed